N-(3-氯-2-氟苯基)-7-甲氧基-6-(哌啶-4-氧基)喹唑啉-4-胺 、 异氰酸甲酯 在
silica gel 、 氨 、 二氯甲烷 作用下,
以
二氯甲烷 为溶剂,
反应 4.0h,
以to give the title compound as a white solid (100 mg, 72%)的产率得到4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl)piperidin-4-yl]oxy}quinazoline
[EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
申请人:ASTRAZENECA AB
公开号:WO2005028469A1
公开(公告)日:2005-03-31
The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
The invention concerns quinazoline derivatives of Formula (I): wherein each of R
1
, X
1
, R
2
, R
3
, R
5
, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
申请人:Astrazeneca AB
公开号:US08318752B2
公开(公告)日:2012-11-27
The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
The invention concerns quinazoline derivatives of Formula I:
wherein each of R
1
, X
1
, R
2
, R
3
, R
5
, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.